

8/10/07

Date Mailed: August 10, 2007

Sheet 1 of 3

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: Haque	
	Filing Date: December 3, 2003	Group Art Unit: 1614

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	<del>6,043,259</del>	<del>3/28/2000</del>	<del>Dhalla et al.</del>			<del>duplicate</del>
PS	6,051,585	04/18/2000	Weinstein et al.			
	<del>6,339,086 B1</del>	<del>01/15/2002</del>	<del>Haque</del>			<del>duplicate</del>
PS	6,417,204 B1	07/09/2002	Haque			
PS	6,489,345	12/3/2002	Sethi			
	6,548,519 B1	04/15/2003	Haque			
	<del>6,586,414</del>	<del>7/1/2003</del>	<del>Haque et al.</del>			<del>duplicate</del>
PS	6,605,612 B2	08/12/2003	Haque			
PS	6,667,315 B2	12/23/2003	Haque			
PS	6,677,356	1/13/2004	Sethi et al.			
PS	6,780,997 B2	08/24/2004	Haque			
PS	6,861,439 B2	03/01/2005	Haque et al.			
PS	6,867,215 B2	03/15/2005	Haque			
PS	6,890,943 B2	05/10/2005	Haque			
PS	6,897,228 B2	05/24/2005	Haque			
PS	7,105,673 B2	09/12/2006	Haque			
PS	7,115,625 B2	10/03/2006	Sethi et al.			
PS	7,115,626 B2	10/03/2006	Sethi et al.			
PS	7,125,889 B2	10/24/2006	Sethi et al.			
PS	7,132,430 B2	11/07/2006	Sethi et al.			
PS	7,144,892 B2	12/05/2006	Sethi et al.			
PS	7,148,233 B2	12/12/2006	Sethi et al.			
PS	7,230,009 B2	06/12/2007	Haque et al.			
PS	2004/0186077	09/23/2004	Diakur et al.			
	<del>10/215,739</del>		<del>Sethi</del>			<del>8-8-2002</del>
	<del>10/549,505</del>					
	<del>10/551,302</del>					
	<del>10/551,303</del>					
	<del>10/584,332</del>					

EXAMINER P. Spivack	DATE CONSIDERED 10/25/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: Haque	
	Filing Date: December 3, 2003	Group Art Unit: 1614

<del>10/732,037</del>					
<del>10/881,864</del>		Sethi			<del>8-10-2004</del>
<del>10/974,707</del>					
<del>10/974,718</del>					
<del>11/016,737</del>					
<del>11/177,248</del>					
<del>11/202,272</del>		Friesen			<del>8-10-2005</del>
<del>11/262,509</del>					
<del>11/288,971</del>					
<del>11/326,201</del>					
<del>11/424,069</del>		Friesen			<del>6-14-2006</del>
<del>11/569,192</del>					
<del>11/631,726</del>					
<del>11/662,351</del>					
<del>11/663,824</del>					
<del>11/672,140</del>					
<del>11/720,422</del>					
<del>11/739,920</del>					

## FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PS	Bässler, "Megavitamin Therapy with Pyridoxine", <i>Internat. J. Vit. Nutr. Res.</i> 58: 105-118 (1988) •
PS	Banaa et al., "Homocysteine lowering and cardiovascular events after acute myocardial infarction", <i>N. Eng. J. Med.</i> 354: (2006); DOI:10.1056/NEJM01055227 (including supplementary appendix) •
PS	Chumnantana et al., "Vitamin B <sub>6</sub> compounds prevent the death of yeast cells due to menadione, a reactive oxygen generator", <i>Biochimica et Biophysica Acta</i> 1722:84-91 (2005) •
PS	Higuchi et al. "Aminophospholipid glycation and its inhibitor screening system: A new role of pyridoxal 5'-phosphate and pyridoxal as lipid glycation inhibitor", <i>J Lipid Res.</i> 2006 Feb 9; doi:10.1194/jlr.M500348-JLR200.
PS	Hirai et al., "Cerebrospinal fluid somatostatin in West syndrome: changes in response to combined treatment with high-dose pyridoxal

EXAMINER	Phyllis Spivack	DATE CONSIDERED	10/25/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: Haque	
	Filing Date: December 3, 2003	Group Art Unit: 1614

		phosphate and low-dose corticotropin", <i>Neuropeptides</i> 32(6):581-586 (1998).
PS		Holman, "Pyridoxine - Vitamin B-6", <i>J. Austral. Coll. Nutr. Environ. Med.</i> 14: 5-16 (1995).
PS		Kannan et al., "Effect of Vitamin B6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H2O2-treated U937 monocytes", <i>Free Radical Biol. Med.</i> 36: 423-428 (2004).
		Kolata, "Studies suggest B vitamins don't prevent heart attacks", <i>N.Y. Times</i> , March 13, 2006 at page 14, section A, column 3.
PS		Kuo et al. "Pyridoxal phosphate-responsive epilepsy with resistance to pyridoxine", <i>Pediatr. Neurol.</i> 26: 146-147 (2002).
PS		Ohtsuka et al., "Treatment of the West Syndrome with High-Dose Pyridoxal Phosphate", <i>Brain &amp; Development</i> 9(4):418-421 (1987).
PS		Schaumburg et al., "Sensory neuropathy from pyridoxine abuse", <i>N. Eng. Med. J.</i> 309: 445-448 (1983).
PS		Seki, "Combination Treatment of High-Dose Pyridoxal Phosphate and Low-Dose ACTH in Children with West Syndrome and Related Disorders", <i>The Japanese Journal of Psychiatry and Neurology</i> 44(2):219-237 (1990).
PS		Ubbink et al., "Effect of different levels of oral pyridoxine supplementation on plasma pyridoxal-5'-phosphate and pyridoxal levels and urinary vitamin B-6 excretion," <i>Am. J. Clin. Nutr.</i> 46: 78-85 (1987).
PS		Wang et al., "Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy" <i>Arch. Dis. Child.</i> 90: 512-515 (2005).
PS		The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators, "Homocysteine lowering with folic acid and B vitamins in vascular disease" <i>N. Eng. J. Med.</i> 354: (2006); DOI:10.1056/NEJM060900 (including supplementary appendix).
PS		"Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline" A Report on the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline and Subcommittee on Upper Reference Levels of Nutrients, Food and Nutrition Board, Institute of Medicine (1998) (ISBN 0-309-06554-2).

EXAMINER <i>P. Spivack</i>	DATE CONSIDERED <i>10/24/07</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	